Adaptive Biotechnologies (NASDAQ:ADPT) Downgraded by Zacks Investment Research
Adaptive Biotechnologies (NASDAQ:ADPT – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Monday, Zacks.com reports. According to Zacks, “Adaptive Biotechnologies Corporation is a commercial-stage biotech company. It develops and commercializes immune-driven clinical products to transform the diagnosis and treatment of disease. […]
United States New Jersey Morgan Stanley Segall Bryant Hamill Adaptive Biotechnologies Corporation Zacks Investment Research
Source: etfdailynews.com